Zelboraf (vemurafenib) / Daiichi Sankyo, Roche 
Welcome,         Profile    Billing    Logout  

89 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zelboraf (vemurafenib) / Roche
ChiCTR-OPC-17013601: Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

Not yet recruiting
4
30
 
vemurafenib
Navy General Hospital of PLA; Navy General Hospital of PLA, Self sponsored and hospital sponsored
Craniopharyngioma
 
 
ChiCTR2000033423: A prospective clinical study of vemurafenib sequential cytarabine in children with refractory Langerhans cell histiocytosis and BRAF V600E mutation

Recruiting
4
12
 
vemurafenib sequential cytarabine
West China Second University Hospital, Sichuan University; West China Second University Hospital, Sichuan University, Self sponsored and hospital sponsored
Langerhans cell histiocytosis
 
 
COLUMBUS, NCT01909453 / 2013-001176-38: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Checkmark 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Jul 2022 - Jul 2022: 5 year data from COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma
Checkmark Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
May 2019 - Jun 2019: Update on OS data of COLUMBUS trial in combination with Mektovi in patients with BRAF V600 mutant melanoma at ASCO 2019 [screenshot]
Checkmark From COLUMBUS trial in combination with binimetinib at SMR 2018 [screenshot]
More
Completed
3
921
Europe, Canada, Japan, US, RoW
LGX818, MEK162, vemurafenib, Zelboraf, PLX4032, RO5185426
Pfizer
Melanoma
11/16
09/24
IMspire150, NCT02908672 / 2016-002482-54: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Checkmark Submission of Cotellic + Tecentriq + Zelboraf in BRAFmut melanoma
Feb 2021 - Feb 2021: Submission of Cotellic + Tecentriq + Zelboraf in BRAFmut melanoma
Checkmark Data from IMspire150 trial in combination with Cotellic and Zelboraf for 1L melanoma
Nov 2020 - Nov 2020: Data from IMspire150 trial in combination with Cotellic and Zelboraf for 1L melanoma
Checkmark Approved in US in combination with Zelboraf and Tecentriq for 1L+ BRAFm melanoma
More
Completed
3
514
Europe, Canada, US, RoW
Atezolizumab, Atezolizumab Placebo, Cobimetinib, Vemurafenib, Vemurafenib Placebo
Hoffmann-La Roche
Melanoma
10/19
07/24
NCT05540951: VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Recruiting
3
78
RoW
VIC, Bevacizumab Plus Chemotherapy
Fudan University
Colorectal Cancer
08/22
12/22
NCT06008119: Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Not yet recruiting
3
165
NA
Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
Shanghai Kechow Pharma, Inc.
Colorectal Cancer Metastatic
12/26
12/26
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, Divarasib, RO7435846; GDC-6036, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
2020-005053-25: To test the safety, efficacy and tolerability of a drug called trametinib and determine the duration of treatment in children with histiocytic cell hyperplasia refractory to conventional therapy. Sprawdzenie bezpieczeństwa, skuteczności i tolerancji leku o nazwie trametinib oraz określenie czasu leczenia u dzieci z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych.

Not yet recruiting
2
12
Europe
Mekinist, Coated tablet, Mekinist
Institute of Mother and Child, Medical Research Agency
histiocytic cell proliferation rozrost komórek histiocytarnych, Neoplasm derived from histiocyte Nowotwór pochodzacy z histiocytów, Diseases [C] - Cancer [C04]
 
 
ACTRN12620000861954p: Cancer Molecular Screening and Therapeutics (MoST) Program and ASPiRATION subprogram, Addendum 12 – substudies 27-30: Vemurafenib and Cobimetinib

Not yet recruiting
2
64
 
University of Sydney, Office for Health and Medical Research
Cancer; non-small cell lung cancer
 
 
2011-005487-13: Study of the clinical activity and safety of vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia carrying the BRAF-V600E mutation Studio sull’attivita' clinica e la sicurezza di vemurafenib (PLX-4032), in pazienti con Leucemia a Cellule Capellute positivi alla mutazione BRAF-V600E e precedentemente trattati.

Ongoing
2
25
Europe
Film-coated tablet, Zelboraf
UNIVERSITA' DEGLI STUDI DI PERUGIA, F. Hoffmann-La Roche Ltd
Hairy cell leukemia (HCL)carrying the BRAF-V600 mutation Leucemia a cellule capellute positiva alla mutazione del gene BRAF-V600, B lymphocytes cancer tumore dei linfociti B, Diseases [C] - Cancer [C04]
 
 
2014-003046-27: STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF VEMURAFENIB (ZELBORAF) IN COMBINATION WITH MONOCLONAL ANTIBODY RITUXIMAB (MABTHERA) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION

Ongoing
2
10
Europe
vemurafenib, Rituximab, Film-coated tablet, Solution for infusion, ZELBORAF, MabThera
Dipartimento di Medicina, Dipartimento di Medicina Università di Perugia
HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION, B lymphocytes cancer, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation

Active, not recruiting
2
100
RoW
Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032
Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU
Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers
07/15
05/18
2013-000280-84: Treatment of patients with advanced melanoma with chemotherapy + Interferon combined with vemurafenib (BRAF-mutation positive patients) or chemotherapy +Interferon (BRAF-mutation negative patients) Paikallisesti levinneen tai etäpesäkkeitä lähettäneen melanooman hoito yhdistelmäsytostaattihoidolla ja interferonilla sekä vemurafenibilla (BRAF-mutaatio positiiviset potilaat) tai ilman (BRAF-mutaatio negatiiviset potilaat)

Ongoing
2
120
Europe
Zelboraf, Zelboraf, Zelboraf
Finnish melanoma group, Roche Oy
Patients with histologically confirmed metastatic melanoma
 
 
2015-004960-12: EQUENTIAL THERAPY WITH VEMURAFENIB AND ELECTROCHEMOTHERAPY FOR IN-TRANSIT MELANOMA METASTASES Terapia sequenziale con Vemurafenib ed elettrochemioterapia nei pazienti con melanoma cutaneo e metastasi in transito

Ongoing
2
53
Europe
Zelboraf, EU/1/12/751/001, Film-coated tablet, Concentrate for solution for injection, ZELBORAF - 240 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE, BLEOMICINA - 15 U POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE POLVERE + 1 FIALA SOLVENTE DA 5 ML, CISPLATINO ACCORD HEALTHCARE ITALIA - 1MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10 ML
INTERGRUPPO MELANOMA ITALIANO, Roche
melanoma BRAF V600 mutated melanoma BRAFV600 mutato, melanoma melanoma, Diseases [C] - Cancer [C04]
 
 
2017-001836-20: STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARMS, ITALIAN, MULTICENTER STUDY (HCL-PG04) COMBINAZIONE SEQUENZIALE DI OBINUTUZUMAB, VEMURAFENIB E COBIMETINIB IN PAZIENTI CON LEUCEMIA A CELLULE CAPELLUTE (HAIRY CELL LEUKEMIA – HCL) PRECEDENTEMENTE TRATTATI CON ANALOGHI DELLE PURINE O NON IDONEI ALLA CHEMIOTERAPIA: STUDIO ITALIANO DI FASE II, MULTICENTRICO, A SINGOLI BRACCI (HCL-PG04)

Ongoing
2
42
Europe
obinutuzumab, Vemurafenib, cobimetinib, -, Solution for infusion, Film-coated tablet, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, ZELBORAF - 240 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA, Fondi del Dip. Medicina e contributo Roche
HCL patients carrying the BRAF-V600E mutation pazienti con HCL positivi alla mutazione BRAF-V600E, patients with Hairy Cell Leukemia carrying the BRAF-V600E mutation pazienti affetti da Leucemia a Cellule Capellute positivi alla mutazione BRAF-V600E, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
AcSé, NCT02304809 / 2014-001225-33: Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Checkmark From AcSé trial for BRAF V600-mutated NSCLC
Mar 2020 - Mar 2020: From AcSé trial for BRAF V600-mutated NSCLC
Active, not recruiting
2
216
Europe
Vemurafenib, Zelboraf
UNICANCER, National Cancer Institute, France, Fondation ARC, Hoffmann-La Roche
Solid Tumors, Hematologic Cancers, Metastatic Cancers
05/19
10/27
2016-003279-23: Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY) Fase 2 Studie met de COmbinatie van Vemurafenib en Cobimetinib in BRAF V600 gemuteerde Melanoma Patiënten om LDH te normaliseren en immunotherapie met Nivolumab en Ipilimumab te optimaliseren (COWBOY)

Not yet recruiting
2
200
Europe
Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy, Cotellic, Zelboraf
Radboudumc, Bristol-Myers Squibb International Corporation
Stage IV or unresectable stage III, BRAFV600E/K mutation positive melanoma, naïve for BRAF/MEK, PD-1/PD-L1 or CTLA-4 targeting therapy, Advanced melanoma, Diseases [C] - Cancer [C04]
 
 
2019-004771-40: ProTargetA Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling

Not yet recruiting
2
300
Europe
Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo
Rigshospitalet, Roche, Pfizer
Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04]
 
 
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway

Not yet recruiting
2
2000
Europe
Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula
Oslo University Hospital, Oslo University Hospital
Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04]
 
 
2020-005052-37: To check the safety, efficacy and tolerability of the drug vemurafenib, and to determine the duration of treatment in children with BRAF mutation-resistant histiocytic cell hyperplasia resistant to conventional therapy. Sprawdzenie bezpieczeństwa, skuteczności i tolerancji leku o nazwie wemurafenib oraz określenie czasu leczenia u dzieci z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF.

Not yet recruiting
2
25
Europe
ZELBORAF, Film-coated tablet, ZELBORAF
Institute of Mother and Child, Medical Research Agency
histiocytic cell proliferation rozrost komórek histiocytarnych, Neoplasm derived from histiocyte Nowotwór pochodzący z histiocytów, Diseases [C] - Cancer [C04]
 
 
2019-003192-18: Phase II clinical trial with early efficacy testing and adaptive extension for rare malignant tumors

Not yet recruiting
2
175
Europe
Alectinib, Tecentriq, Vemurafenib, Cobimetinib, Ipatasertib, Herceptin, Perjeta, Inavolisib, 7113755, Capsule, hard, Infusion, Film-coated tablet, Powder for infusion, Concentrate for solution for infusion, Tecentriq, Herceptin, Perjeta
German Cancer Research Center, German Cancer Research Center, Roche Pharma AG
Metastatic or locally advanced malignancies, Previously Treated Advanced tumours, Diseases [C] - Cancer [C04]
 
 
Tricotel, NCT03625141 / 2018-000759-41: A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Completed
2
80
Europe, RoW
Cobimetinib, Cotellic, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf
Hoffmann-La Roche
Metastatic Melanoma
06/21
04/23
NCT01659151: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Active, not recruiting
2
17
US
High Dose Interleukin-2 (IL-2), aldesleukin, Proleukin, ACT with TIL Infusion, Vemurafenib, Zelboraf, B-Raf enzyme inhibitor, Lymphodepletion, fludarabine, Fludara, cyclophosphamide, Neostar, Cytoxan
H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma
10/21
12/24
2021-000689-14: Finnish national phase 2 study to evaluate targeted drug treatment in advanced cancer. Yksilöllistä syövänhoitoa selvittävä kansallinen vaiheen 2 lääketutkimus edenneessä syövässä.

Not yet recruiting
2
250
Europe
abemaciclib, pralsetinib, Tablet, Capsule, hard, Injection, Infusion, Capsule, Stivarga, Alecensa, Cotellic, Erivedge, Phesgo, Rozlytrek, Tecentriq, Zelboraf, Verzenios, Retsevmo, Erleada, Tafinlar, Mekinist, Gavreto, Lynparza
Helsinki University Hospital, Helsinki University Hospital
Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test., Patients with advanced cancer where standard treatment options no longer exist. Potilaat, jotka sairastava edennyttä syöpää, johon tavanomaiset hoitolinjat eivät enää tehoa., Diseases [C] - Cancer [C04]
 
 
NCT02638428: Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Recruiting
2
90
RoW
CancerSCAN™, Ifosfamide, Carboplatin, Etoposide, Fludarabine, Cytarabine, Pazopanib, Sorafenib, Axitinib, Crizotinib, Dasatinib, Erlotinib, Everolimus, Imatinib, Ruxolitinib, Vandetanib, Vemurafenib, Trastuzumab
Samsung Medical Center, Ministry of Health, Republic of Korea
Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML, Refractory Pediatric AML
12/21
12/23
NCT03727763: Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

Recruiting
2
30
RoW
Vemurafenib, PLX4032, RG7204, Cetuximab, ERBITUX
Shanghai Changzheng Hospital
Colorectal Cancer
12/21
12/22
NCT03220035: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Active, not recruiting
2
4
US
Laboratory Biomarker Analysis, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX 4032, PLX-4032, PLX4032, RG 7204, RG-7204, RG7204, RO 5185426, RO-5185426, Zelboraf
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
06/22
09/25
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors

Not yet recruiting
2
770
NA
Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rare Tumor
07/22
07/23
COWBOY, NCT02968303: Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

Recruiting
2
200
Europe
Vemurafenib and Cobimetinib
Radboud University Medical Center, The Netherlands Cancer Institute, Isala
Melanoma, Malignant, of Soft Parts
10/22
10/23
2021-001864-12: VEMURAFENIB + RITUXIMAB (VR) AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE + RITUXIMAB (CDAR) IN FRONT-LINE HAIRY CELL LEUKEMIA (HCL): A PHASE-2 RANDOMIZED MULTICENTER TRIAL VEMURAFENIB + RITUXIMAB (VR) COME ALTERNATIVA NON CHEMIOTERAPICA A CLADRIBINA + RITUXIMAB (CDAR) NEL TRATTAMENTO DI PRIMA LINEA DELLA TRICOLEUCEMIA: UNO STUDIO MULTICENTRICO RANDOMIZZATO DI FASE-2

Not yet recruiting
2
120
Europe
Rituximab, cladribina, Vemurafenib, [L01X- C02], [NA], L01XE15, Concentrate for solution for infusion, Solution for injection, Tablet, MABTHERA - 1 FIALA 500 MG 50 ML, LITAK - 2MG/ML SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLAC. (VETRO) 5 ML 5 FLACONCINI, MABTHERA - 2 FIALE 100 MG 10 ML, ZELBORAF - 240 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
DIPARTIMENTO DI MEDICINA, UNIVERSITà DI PERUGIA, Fondi del Dipartimento di Medicina e Chirurgia
Previously untreated patients with diagnosis of HCL Pazienti precedentemente non trattati con diagnosi di HC, Previously untreated patients with diagnosis of HCL Pazienti precedentemente non trattati con diagnosi di HC, Diseases [C] - Cancer [C04]
 
 
RadioCoBRIM, NCT03430947 / 2017-000768-13: Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Terminated
2
20
Europe
Vemurafenib, Cobimetinib
Technische Universität Dresden
Malignant Melanoma Stage IV, BRAF V600 Mutation, Brain Metastases
02/23
02/23
CUPISCO, NCT03498521 / 2017-003040-20: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Active, not recruiting
2
528
Europe, Japan, RoW
Alectinib, Vismodegib, Ipatasertib, Olaparib, Erlotinib, Bevacizumab, Vemurafenib, Cobimetinib, Trastuzumab Subcutaneous (SC), Pertuzumab, Atezolizumab, Carboplatin, Paclitaxel, Cisplatin, Gemcitabine, Entrectinib, Ivosidenib, Pemigatinib
Hoffmann-La Roche, Foundation Medicine, Inc.
Cancer of Unknown Primary Site
02/23
06/24
NCT03585686: A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

Recruiting
2
12
RoW
Vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Langerhans Cell Histiocytosis
04/23
12/23
NCT03514901 / 2017-003038-98: To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Active, not recruiting
2
120
Europe
Experimental combination beyond Focal Progression, Pembrolizumab or Nivolumab, Keytruda or Opdivo
Intergruppo Melanoma Italiano
Melanoma Metastatic, BRAF V600 Mutation
04/23
04/23
NCT02091141: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Checkmark ASCO 2016
Jun 2016 - Jun 2016: ASCO 2016
Checkmark ASCO-GI 2016
Jan 2016 - Jan 2016: ASCO-GI 2016
Completed
2
673
US
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Erlotinib, Tarceva, Vemurafenib, Zelboraf, Cobimetinib, Cotellic, Vismodegib, Erivedge, Alectinib, Alecensa, Atezolizumab, Tecentriq
Genentech, Inc.
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
05/23
05/23
NCT03239015: Efficacy and Safety of Precision Therapy in Refractory Tumor

Recruiting
2
300
RoW
Gefitinib, Erlotinib, Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib, Dabrafenib, Palbociclib, PD-1/L1 inhibitor plus anti-angiogenic agent
Baodong Qin
Rare Tumor, Refractory Tumor
06/23
12/23
NCT03224767: Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Active, not recruiting
2
24
US
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
BRAF V600E Mutation Present, Papillary Craniopharyngioma
10/24
08/26
NEO-TIM, NCT04722575 / 2018-004841-17: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting
2
95
Europe
Cobimetinib 20 MG Oral Tablet, Cotellic, Vemurafenib 240 Mg Oral Capsule, Zelboraf, Atezolizumab 1200 MG in 20 ML Injection, Tecentriq
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Melanoma
12/23
06/27
ACTRN12620000861954: Cancer Molecular Screening and Therapeutics (MoST) Program and ASPiRATION subprogram, Addendum 12 – substudies 27-30: Vemurafenib and Cobimetinib

Active, not recruiting
2
64
 
University of Sydney, Office for Health and Medical Research , Australian Genomic Cancer Medicine Centre (AGCMC)
Cancer, non-small cell lung cancer
 
 
ChiCTR2000039310: Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Recruiting
2
208
 
Almonertinib, 110mg, qd ;Dacomitinib, 450mg, qd ;Alectinib, 600mg, bid ;Crizotinib, 250mg, bid ;Zelboraf, 960mg, bid ;Niraparib,200-300mg,qd ;Pyrotinib, 400mg, qd ;Imatinib, 400mg, bid ;Palbociclib, 125mg,*21d, q28d ;Sintilimab, 200mg, q21d ;Atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d
National Cancer Center/National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised
Rare Tumors
 
 
NCT03410875: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Active, not recruiting
2
30
US
Vemurafenib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Yale University
Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell
01/25
01/25
NCT05233332: Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

Recruiting
2
186
RoW
HL-085, Vemurafenib, ZELBORAF
Shanghai Kechow Pharma, Inc.
CRC
01/24
07/24
NCT02036086: Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Active, not recruiting
2
24
Canada
Vemurafenib, Zelboraf, Cobimetinib, GDC-0973
Sunnybrook Health Sciences Centre
Melanoma
01/24
01/24
ImmunoCobiVem, NCT02902029 / 2015-005097-37: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Completed
2
186
Europe, RoW
Vemurafenib, Cobimetinib, Atezolizumab
University Hospital, Essen
Malignant Melanoma
03/24
03/24
NAUTIKA1, NCT04302025: A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Recruiting
2
125
US
Alectinib, Entrectinib, Vemurafenib (Enrollment closed), Cobimetinib (Enrollment closed), Pralsetinib (Enrollment closed), Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Genentech, Inc., Blueprint Medicines Corporation
Non-small Cell Lung Cancer
12/25
03/29
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
NeoACTIVATE, NCT03554083: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Recruiting
2
30
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Tiragolumab, MTIG7192A, RG6058, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf
Mayo Clinic, National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
06/25
06/25
NCT05068752: Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Active, not recruiting
2
12
US
Vemurafenib, Sorafenib
HonorHealth Research Institute, Bayer, Genentech, Inc.
Pancreas Cancer
10/24
12/24
IMPROVEMENT-2, NCT06603376: Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

Recruiting
2
75
RoW
FOLFIRI + Vemurafenib + Cetuximab, FOLFIRI ± Bevacizumab
Shanghai Changzheng Hospital
Colorectal Carcinoma
08/26
12/26
NCT06561360: A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People with Hairy Cell Leukemia (HCL)

Recruiting
2
86
US
Vemurafenib, Obinutuzumab, Cladribine, Rituximab
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Hairy Cell Leukemia
09/27
09/27
NCT05263453: HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Recruiting
2
104
RoW
HL-085, Vemurafenib
Shanghai Kechow Pharma, Inc.
Melanoma
09/24
12/24
DARWIN II, NCT02314481: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting
2
50
Europe
MPDL3280A, Atezolizumab, Vemurafenib, Zelboraf, Alectinib, Alecensa, Trastuzumab emtansine, T-DM1, Kadcyla
University College, London, Hoffmann-La Roche
Non-small Cell Lung Cancer
05/26
05/26
NCT06440850: Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Recruiting
2
21
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Diagnostic Imaging, Medical Imaging, I-131 Uptake Test, I 131 Uptake, I-131 Uptake and Scan, Radioactive Iodine Uptake, Iodine I-131, 131-Iodine, Bound Iodide I-131, I 131, I-131, Iodide I-131, Iodide, I-131, Iodine 131, Iodine-131, Iodotope, Iodotrope, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Recombinant Thyrotropin Alfa, Recombinant Thyrotropin Alpha, Recombinant TSH Alpha, Thyrogen, Thyroid Stimulating Hormone Alpha, Thyrotropin Alfa, TSH-alpha, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf
City of Hope Medical Center, National Cancer Institute (NCI)
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
11/26
11/26
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
IRB-21-7787, NCT05388123: Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Recruiting
2
20
US
Low dose vemurafenib plus rituximab, Vemurafenib, Rituximab
Scripps Health
Hairy Cell Leukemia
01/25
01/25
CRAFT, NCT04551521 / 2019-003192-18: The NCT-PMO-1602 Phase II Trial

Recruiting
2
175
Europe
Vemurafenib, Cobimetinib, Atezolizumab, Trastuzumab, Pertuzumab, Alectinib, Ipatasertib, Inavolisib
German Cancer Research Center, German Cancer Research Center, Roche Pharma AG
Metastatic or Locally Advanced Malignancies
06/25
06/25
NCT03181100: Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Active, not recruiting
2
50
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Carcinoma
07/25
07/25
NCT05900219: Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Not yet recruiting
2
75
NA
HL-085+Vemurafenib
Shanghai Kechow Pharma, Inc.
Non-small-cell Lung Cancer
09/25
09/25
NCT01711632: BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

Completed
2
36
US
Vemurafenib, Zelboraf™
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Northwestern University, Ohio State University, Dana-Farber Cancer Institute, Scripps Clinic, Northwell Health
Hairy Cell Leukemia
08/24
08/24
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
TRAM, NCT04943224: Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Recruiting
2
12
Europe
Trametinib, Mekinist
Anna Raciborska, Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wrocław University of Environmental and Life Sciences
Histiocytosis
03/26
03/26
BRAVO, NCT04943198: Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Recruiting
2
25
Europe
Vemurafenib, Zelboraf
Anna Raciborska, Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wrocław University of Environmental and Life Sciences
Histiocytosis
03/26
03/26
NCT01709292: Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Active, not recruiting
2
24
US
Vemurafenib (All Groups), PLX4032, RO5185426, Zelboraf™, Vemurafenib (Post Surgery) - Group A + C, Post Surgery - Group B
M.D. Anderson Cancer Center, Genentech, Inc.
Thyroid Cancer
09/26
09/26
FINPROVE, NCT05159245 / 2021-000689-14: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Tepotinib, Tepmetko, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pemigatinib, Pemazyre
Helsinki University Central Hospital, Helsinki University Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
MATCH, NCT03155620: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric Screening Trial)

Recruiting
2
2316
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ensartinib, Ensacove, X 396, X-396, X396, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Laboratory Biomarker Analysis, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mutation Carrier Screening, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Samotolisib, 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-, LY 3023414, LY-3023414, LY3023414, WHO 10889, Selpercatinib, LOXO 292, LOXO-292, LOXO292, RET Kinase Inhibitor LOXO-292, Retevmo, Retsevmo, WHO 10967, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Tazemetostat, E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438, Tipifarnib, R115777, Zarnestra, Ulixertinib, BVD-523, VRT752271, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX 4032, PLX-4032, PLX4032, RG 7204, RG-7204, RG7204, RO 5185426, RO-5185426, Zelboraf, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
09/27
09/27
IMPRESS-Norway, NCT04817956 / 2020-004414-35: Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
2
3000
Europe
Atezolizumab, Atezolizumab combined with bevacizumab, Phesgo (trastuzumab og pertuzumab), Alectinib, vismodegib, entrectinib, Vemurafenib and cobemitinib, Niraparib, Dostarlimab, Ceritinib
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna HF, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Cancer Metastatic
03/40
04/45
VIC-BRAFMT-mCRC, NCT04790448: Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Completed
1/2
37
RoW
Cetuximab, C225, Erbitux, Irinotecan, CPT-11, Camptothecin-11, Camptosar, Vemurafenib, Zelboraf
Sun Yat-sen University
Colorectal Cancer Metastatic
12/21
12/21
NCT03101254 / 2017-000429-10: LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Completed
1/2
5
US
LY3022855, Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Dana-Farber Cancer Institute, Eli Lilly and Company
Melanoma
10/20
11/20
NCT01638676: A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

Recruiting
1/2
55
US
Vemurafenib, Vemurafenib branded as Zelboraf, Metformin, Metformin hydrochloride branded as Glucophage
University of Louisville, James Graham Brown Cancer Center
Melanoma
06/25
06/27
NCT02042040: Vemurafenib:Radiation Use During Vemurafenib Treatment

Not yet recruiting
1
36
US
Vemurafenib
University of Utah
Melanoma
12/16
12/16
NCT01748149: Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Active, not recruiting
1
40
Canada, US
Vemurafenib, RO5185426, PLX4032
University of California, San Francisco, Genentech, Inc.
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
12/18
12/25
NCT02721459: XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Active, not recruiting
1
26
US
XL888, HSP90 inhibitor, Vemurafenib, Zelboraf ®, Cobimetinib, GDC-0973/XL518
H. Lee Moffitt Cancer Center and Research Institute, Exelixis, Genentech, Inc.
Melanoma, Skin Cancer
10/19
10/24
NCT05019534: Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

Recruiting
1
12
RoW
Vemurafenib Oral Tablet [Zelboraf], Zelboraf, Cetuximab Injection [Erbitux], Erbitux, Camrelizumab
West China Hospital
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
08/22
12/22
NCT03781219: A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Recruiting
1
45
RoW
HL-085, Vemurafenib, ZELBORAF
Shanghai Kechow Pharma, Inc.
Solid Tumor
12/23
12/23
NCT04462471: Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Completed
1
8
US
I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
Memorial Sloan Kettering Cancer Center
Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell), Thyroid Cancer, Papillary, BRAF V600E Mutation Positive
09/23
09/23
NCT01787500: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Active, not recruiting
1
33
US
Cetuximab, Cetuximab Biosimilar CMAB009, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, U-101440E, Laboratory Biomarker Analysis, Pharmacological Study, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Genentech, Inc.
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
03/26
03/26
NCT03543969: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Recruiting
1
13
US
Encorafenib, BRAFTOVI, BRAF/MEK-inhibitor, Binimetinib, MEKTOVI, Nivolumab, Opdivo
H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
09/24
09/28
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated
N/A
3
RoW
Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Cancer
12/22
12/22
OCEANMIST, NCT05260684: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Completed
N/A
1
US
Encorafenib, Administration route: Oral, Binimetinib, Vemurafenib, Cobimetinib, Dabrafenib, Trametinib
Pfizer
Melanoma
12/23
12/23
NCT02145143: Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Active, not recruiting
N/A
12
US
Vemurafenib, RO5185426,, PLX4032, RG7204, serial 124I PET/CT, thyrotropin alpha, Thyrogen, Genzyme
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Thyroid Carcinoma
05/25
05/25
KOSMOS-II, NCT05525858: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting
N/A
1000
RoW
Alectinib, Alecensa, Atezolizumab, Tecentriq, Erlotinib, Tarceva, Trastuzumab + Pertuzumab, Herceptin + Perjeta, Trastuzumab emtansine, Kadcyla, Vemurafenib, Zelboraf, Bevacizumab + Erlotinib, Avastin + Tarceva, Entrectinib, Rozlytrek, Pralsetinib, Gavreto
Seoul National University Bundang Hospital, Korean Cancer Study Group, Roche Pharma AG
Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
09/26
03/27
NCT05177666: a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Not yet recruiting
N/A
120
NA
Targeted therapy, Entratinib, Cabotinib, Aletinib, Enmetrastuzumab, Trastuzumab, Pertuzumab, Vemurafenib, Atilizumab, Bevacizumab, Erlotizumab
The University of Hong Kong-Shenzhen Hospital, Tianjin Happy Life Technology Co., Ltd.
Feasibility, Effectiveness, Safety, Targeted Molecular Therapy
12/23
03/24

Download Options